<DOC>
	<DOCNO>NCT01249157</DOCNO>
	<brief_summary>Positron Emission Mammography ( PEM ) newly develop image examination breast use radioactive glucose base tracer , form sugar attach low radiation agent , detect cancer cell . The radioactive glucose base tracer call fluorodeoxyglucose ( FDG ) , FDA approve . A PEM scanner able well detect cancer cell within breast , regular PET scanner . The PEM scanner also FDA approve . This type imaging may able see breast cancer could see mammogram may good good breast MRI . The purpose study compare value FDG Positron Emission Mammography ( PEM ) contrast enhance Magnetic Resonance Imaging ( MRI ) breast patient breast cancer . This study also perform special pathology test compare FDG PEM contrast enhance breast MRI image result standard care breast surgery . This may teach u biology breast tumor .</brief_summary>
	<brief_title>Histologic Assessment Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography ( PEM ) Magnetic Resonance Imaging ( MRI ) Breast</brief_title>
	<detailed_description />
	<criteria>Female patient recently diagnose invasive situ breast cancer core needle biopsy FNA ( confirm MSKCC ) prior enrollment . Patients plan treatment mastectomy MSKCC . Patients 21 year old old . Patients breast MRI within 30 day less PEM . Patients digital mammogram . Patients pregnant breast feed . Patients prior radiation therapy endocrine therapy . Patients prior lumpectomy . Patients diabetic . Patients moderate end stage kidney disease . Patients contraindication MRI ( i.e . pacemaker , metallic implant , etc ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>MRI</keyword>
	<keyword>PEM</keyword>
	<keyword>10-189</keyword>
</DOC>